OR WAIT 15 SECS
Melanie Sena is community editor of Pharmaceutical Technology.
DSM Pharmaceutical Products opens a cGMP facility for biopharmaceutical contract manufacturing in Brisbane, Australia.
DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM, has opened a new cGMP facility for biopharmaceutical contract manufacturing in Brisbane, Australia. The facility was built in partnership with Biopharmaceuticals Australia with cooperation from the government of Queensland and the Commonwealth of Australia.
The Brisbane facility offers cGMP mammalian cell-culture contract manufacturing services from process development through to commercial manufacturing.
DSM Biologics, the business unit of DSM Pharmaceutical Products that operates the Brisbane facility, also offers process development and cGMP manufacturing in Groningen, The Netherlands. DSM previously announced contracts for the Brisbane site with DecImmune Therapeutics of Cambridge, Massachusetts, Recepta Biopharma of São Paulo, Brazil, Paranta Biosciences of Melbourne, Australia, and Opthea of Melbourne, Australia. The Brisbane facility has an output capability of 500 kg and has expansion space available for further capacity utilization.
Source: DSM Pharmaceutical
Related Content:Industry News